Gilead Sciences (GILD) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

Today's Research Daily features new research reports on 16 major stocks, including Uber Technologies, Inc. (UBER), Comcast Corp. (CMCSA) and Gilead Sciences, Inc. (GILD), as well as a micro-cap ...

Bullish option flow detected in Gilead (GILD) with 14,401 calls trading, 4x expected, and implied vol increasing over 4 points to 27.50%. Feb-25 102 calls and 2/14 weekly 95 puts are the most ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with the rare liver disease primary biliary cholangitis (PBC) ...

Following this transaction, Dickinson holds 129,873 shares of Gilead Sciences. The sale was made under a Rule 10b5-1 trading plan, which was adopted on August 29, 2024.

With the FDA approval of Gilead's seladelpar, there have now been two in a matter of weeks. The US agency has cleared seladelpar under the Livdelzi brand name as a second-line therapy for PBC in ...